Medtronic PLC $MDT Shares Newly Acquired by Convergence Financial LLC

Posted by Brian Himes on Oct 29th, 2026

Convergence Financial LLC acquired a new stake in Medtronic PLC (NYSE:MDT – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 9,769 shares of the medical technology company’s stock, valued at approximately $843,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management boosted its position in Medtronic by 470.9% during the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 259 shares during the period. IAG Wealth Partners LLC acquired a new position in Medtronic during the second quarter valued at approximately $30,000. Pin Oak Investment Advisors Inc. acquired a new position in Medtronic during the second quarter valued at approximately $32,000. Community Bank N.A. bought a new position in shares of Medtronic in the second quarter valued at approximately $33,000. Finally, Core Capital Management & Research inc. bought a new position in shares of Medtronic in the second quarter valued at approximately $33,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medtronic

In other news, CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by company insiders.

Medtronic Stock Up 0.8%

MDT opened at $94.70 on Thursday. The business has a 50 day moving average of $91.56 and a 200-day moving average of $88.35. The stock has a market capitalization of $121.14 billion, a price-to-earnings ratio of 23.33, a P/E/G ratio of 2.23 and a beta of 0.55. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.0%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MDT shares. Bank of America boosted their price objective on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Robert W. Baird raised their target price on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday, September 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $92.00 target price on shares of Medtronic in a report on Thursday, September 3rd. Wells Fargo & Company lifted their target price on shares of Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a report on Wednesday, September 2nd. Finally, Truist Financial reissued a “hold” rating and set a $99.00 target price (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Eighteen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.88.

View Our Latest Stock Analysis on MDT

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Exchange-traded funds purchased approximately $18 million of Medtronic shares on October 26, providing evidence of institutional demand and potentially supporting the stock. ETFs Bought $18.0 Million of Medtronic
Positive Sentiment: Analyst commentary highlights Medtronic’s broader growth opportunities and relatively attractive valuation. Potential drivers include new product launches, procedure recovery and expansion in higher-growth medical-device markets. Medtronic: Broader Growth, Attractive Valuation
Positive Sentiment: The global leadless-pacemaker market is forecast to expand at a 12.8% compound annual growth rate through 2036, reaching $4.87 billion. Medtronic’s presence in cardiac rhythm management gives it exposure to this long-term opportunity, although the report is industry-wide rather than company-specific. Global Leadless Pacemakers Market Forecast
Neutral Sentiment: Medtronic’s upcoming fiscal second-quarter 2027 report is the key near-term catalyst. Analysts expect a low-single-digit profit decline, while the company’s latest guidance calls for quarterly EPS of $1.32–$1.34 and full-year EPS of $5.94–$6.00. Results and guidance could determine the next major move. Medtronic’s Q2 2027 Earnings: What to Expect
Negative Sentiment: Medtronic’s latest dividend increase extended its 49-year streak, but the relatively modest raise may be less compelling to income investors than faster payout growth from Abbott and Johnson & Johnson. Medtronic Raised Its Dividend Again

About Medtronic

(Free Report)

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.